Dr. David Nanus has extensive experience related to both solid tumor oncology and hematologic cancers, overseeing the Division of Hematology and Medical Oncology at Weill Cornell for the past 13 years (that has a robust translational and clinical lymphoma program). Dr. Nanus has a thorough understanding of the cancer cellular and molecular biology, as well as clinical care, and is very familiar with the biology and treatment of lymphoma and myeloma.
Dr. Nanus served on the external advisory board of the Center of Biomedical Research Excellence in the Molecular Basis of Human Disease (COBREMBHD) at the University of Kentucky College of Medicine since 2004, and the External Scientific Advisory Committee of the Renal Cancer SPORE at Dana Farber/Harvard Cancer Center also since 2004.
Dr. Nanus also serves on the Executive Board of the Weill Cornell-MSK Cancer Pharmacology Training Grant.
Dr. Nanus’ own clinical and basic research focuses on molecular abnormalities related to the development and treatment of genitourinary cancers, including the use of transgenic models.